Corrosion resistance of heparin/montmorillonite coating on biomedical magnesium alloy

被引：0
|
作者：
Tian J.-R. [1 ]
Li H. [1 ]
Zou Y.-H. [1 ]
Zeng R.-C. [2 ]
机构：
[1] College of Chemical and Biological Engineering, Shandong University of Scicnce and Technology, Qingdao
[2] College of Materials Science and Engineering, Shandong University of Scicnce and Technology, Qingdao
来源：
Surface Technology | 2021年 / 50卷 / 02期
关键词：
Biomaterial; Corrosion resistance; Heparin; Magnesium alloy; Montmorillonite;
D O I：
10.16490/j.cnki.issn.1001-3660.2021.02.008
中图分类号：
学科分类号：
摘要：
To solve the problems such as vascular endothelialization and restenosis caused by magnesium alloy stent, this study aims to prepare heparin (HS)/montmorillonite (MMT) coating with anticoagulant properties on biomedical magnesium alloy and investigate its corrosion resistance. Sodium montmorillonite (Na-MMT) coating was prepared on the surface of AZ31 magnesium alloy by hydrothermal method; and then HS/MMT composite coating was prepared by immersion method. The coating was characterized using scanning electron microscopy (SEM), Fourier infrared spectroscopy (FT-IR) and X-ray diffractometry (XRD). The corrosion resistance of the coating was investigated by means of electricchemical analysis and hydrogen evolution rate measurement. The results showed that the prepared HS-MMT coating was uniform and compact, with coating thickness of 41 µm. The basic elements of montmorillonite and N, S were found in the EDS analysis diagram of HS-MMT coating, and the characteristic peaks of heparin and montmorillonite were found in the FT-IR and XRD images of the coating. Compared with the AZ31 magnesium alloy, the free corrosion potential of HS-MMT coating was increased up to 0.29 V; corrosion current density was decreased by two orders of magnitude; and the average hydrogen evolution rate was 0.016 mL/(cm·h), only 18% of the AZ31 substrate. Therefore, the HS-MMT coating has good corrosion resistance, providing a new scheme for magnesium alloy vascular stents. © 2021, Chongqing Wujiu Periodicals Press. All rights reserved.
引用
收藏
页码：66 / 73
页数：7
相关论文
共 44 条
  • [1] Zheng Y.F., Yang H.T., Research progress in biodegradable metals for stent application[J], Acta metallurgica sinica, 53, 10, pp. 1227-1237, (2017)
  • [2] Fu J.Y., Su Y.C., Qin Y.X., Et al., Evolution of metallic cardiovascular stent materials: A comparative study among stainless steel, magnesium and zinc[J], Biomaterials, 230, (2020)
  • [3] Nishio S., Kosuga K., Igaki K., Et al., Long-term (>10 years) clinical outcomes of first-in-human biodegradable poly-L-lactic acid coronary stents: Igaki-Tamai stents[J], Circulation, 125, 19, pp. 2343-2353, (2012)
  • [4] Wu Y., Shen L., Wang Q., Et al., Comparison of acute recoil between bioabsorbable poly-L-lactic acid Xinsorb stent and metallic stent in porcine model[J], Journal of biomedicine and biotechnology, 2012, (2012)
  • [5] Cui X.S., Zhou C., Zhang H.J., Research progress on degradation behavior of the biodegradable materials for vascular stents[J], Materials reports, 32, 1, pp. 192-195, (2018)
  • [6] Wang X., Shao X.X., Liu B., Et al., Progress in biological properties of biodegradable metal materials and their application in fracture internal fixation[J], Journal of navy medicine, 41, 5, pp. 619-621, (2020)
  • [7] Bowen P.K., Seitz J.M., Guillory R.J., Et al., Evaluation of wrought Zn-Al alloys (1wt%, 3wt%, and 5wt% Al) through mechanical and in vivo testing for stent applications[J], Journal of biomedical materials research: Applied biomaterials, 106, 1, pp. 245-258, (2018)
  • [8] Li N., Zheng Y.F., Novel magnesium alloys developed for biomedical application: A review[J], Journal of materials science & technology, 29, 6, pp. 489-502, (2013)
  • [9] Tan L.L., Yu X.M., Wan P., Et al., Biodegradable materials for bone repairs: A review[J], Journal of materials science & technology, 29, 6, pp. 503-513, (2013)
  • [10] Erbel R., Di Mario C., Bartunck J., Et al., Temporary scaffolding of coronary arteries with bioabsorbable magnesium sents: A prospective, non-randomised multicentre trial[J], Lancet, 369, 9576, pp. 1869-1875, (2007)
12345